Methods for the alleviation of sexual dysfunction in women

Abstract

This invention relates to a method for inhibition of skin atrophy, or epithelial or mucosal atrophy in women, or to a method for treatment or prevention of symptoms related to said atrophy, said method comprising administering to the woman an effective amount of the compound of formula (I) or a geometric isomer, a stereoisomer, a pharmaceutically acceptable salt, an ester thereof or a metabolite thereof.

1 . A method for treating a female sexual dysfunction disorder, comprising administering a therapeutically effective amount of (deaminohydroxy)torefmifene 
       or a pharmaceutically acceptable salt, ester, or metabolite thereof to a woman during or after menopause; 
       wherein the female sexual dysfunction is selected from the group consisting of: a desire disorder, an arousal disorder, and an orgasmic disorder. 
     
     
         2 - 11 . (canceled) 
     
     
         12 . The method of  claim 1 , wherein the (deaminohydroxy)toremifene or pharmaceutically acceptable salt, ester, or metabolite thereof is administered in a daily dose of 25 mg to 100 mg. 
     
     
         13 . The method of  claim 1 , wherein the (deaminohydroxy)toremifene or pharmaceutically acceptable salt, ester, or metabolite thereof is administered in a daily dose of 30 mg to 90 mg. 
     
     
         14 . The method of  claim 1 , wherein the (deaminohydroxy)toremifene or pharmaceutically acceptable salt, ester, or metabolite thereof is administered in a daily dose of 60 mg. 
     
     
         15 . The method of  claim 1 , wherein the (deaminohydroxy)toremifene or pharmaceutically acceptable salt, ester, or metabolite thereof is administered orally. 
     
     
         16 . The method of  claim 12 , wherein the (deaminohydroxy)toremifene or pharmaceutically acceptable salt, ester, or metabolite thereof is administered orally. 
     
     
         17 . The method of  claim 13 , wherein the (deaminohydroxy)toremifene or pharmaceutically acceptable salt, ester, or metabolite thereof is administered orally. 
     
     
         18 . The method of  claim 14 , wherein the (deaminohydroxy)toremifene or pharmaceutically acceptable salt, ester, or metabolite thereof is administered orally. 
     
     
         19 . The method of  claim 1 , wherein the (deaminohydroxy)toremifene or pharmaceutically acceptable salt, ester, or metabolite thereof is administered for 3 months. 
     
     
         20 . A method of treating a female sexual dysfunction disorder, comprising:
 identifying a female patient in need of treatment for a female sexual dysfunction disorder selected from the group consisting of: a desire disorder, an arousal disorder, and an orgasmic disorder; and   administering to the patient an effective amount of (deaminohydroxy)-toremifene during or after menopause.   
     
     
         21 . The method of  claim 20 , wherein the (deaminohydroxy)toremifene is administered in a daily dose of 25 mg to 100 mg. 
     
     
         22 . The method of  claim 20 , wherein the (deaminohydroxy)-toremifene is administered in a daily dose of 30 mg to 90 mg. 
     
     
         23 . The method of  claim 20 , wherein the (deaminohydroxy)toremifene is administered in a daily dose of 60 mg. 
     
     
         24 . The method of  claim 20 , wherein the (deaminohydroxy)toremifene is administered orally. 
     
     
         25 . The method of  claim 21 , wherein the (deaminohydroxy)toremifene is administered orally. 
     
     
         26 . The method of  claim 23 , wherein the (deaminohydroxy)toremifene is administered orally. 
     
     
         27 . The method of  claim 20 , wherein the (deaminohydroxy)toremifene is administered for 3 months. 
     
     
         28 . The method of  claim 20 , wherein the female sexual dysfunction is a desire disorder. 
     
     
         29 . The method of  claim 20 , wherein the female sexual dysfunction is an arousal disorder. 
     
     
         30 . The method of  claim 20 , wherein the female sexual dysfunction is an orgasmic disorder. 
     
     
         31 . A method for treating a female sexual dysfunction disorder, comprising administering a dose of 25 mg to 100 mg of (deaminohydroxy)toremifene or a pharmaceutically acceptable salt, ester, or metabolite thereof to a female patient during or after menopause, wherein the patient is in need of treatment for a female sexual dysfunction disorder selected from the group consisting of: a desire disorder, an arousal disorder, and an orgasmic disorder. 
     
     
         32 . The method of  claim 31 , wherein the (deaminohydroxy)toremifene or a pharmaceutically acceptable salt, ester, or metabolite thereof is administered orally once a day. 
     
     
         33 . The method of  claim 32 , wherein the dose is from 30 to 90 mg. 
     
     
         34 . The method of  claim 32 , wherein the dose is 60 mg. 
     
     
         35 . The method of  claim 31 , wherein the (deaminohydroxy)toremifene or a pharmaceutically acceptable salt, ester, or metabolite thereof is administered for 3 months. 
     
     
         36 . A method of treating a female sexual dysfunction, comprising orally administering 60 mg (deaminohydroxy)toremifene daily to a female patient during or after menopause in need of treatment for the female sexual dysfunction, wherein the female sexual dysfunction is selected from the group consisting of: a desire disorder, an arousal disorder, and an orgasmic disorder. 
     
     
         37 . The method of  claim 36 , wherein the (deaminohydroxy)toremifene is administered for 3 months. 
     
     
         38 . The method of  claim 36 , wherein the female sexual dysfunction is a desire disorder. 
     
     
         39 . The method of  claim 36 , wherein the female sexual dysfunction is an arousal disorder. 
     
     
         40 . The method of  claim 36 , wherein the female sexual dysfunction is an orgasmic disorder.